Czerwinski DK - Search Results

1

High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.

Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, Timmerman J, Said J, Green MR, Delabie J, Kolstad A, Alizadeh AA, Levy R. Myklebust JH, et al. Among authors: czerwinski dk. Blood. 2013 Feb 21;121(8):1367-76. doi: 10.1182/blood-2012-04-421826. Epub 2013 Jan 7. Blood. 2013. PMID: 23297127 Free PMC article.

2

Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.

Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Kwak LW, et al. Among authors: czerwinski dk. N Engl J Med. 1992 Oct 22;327(17):1209-15. doi: 10.1056/NEJM199210223271705. N Engl J Med. 1992. PMID: 1406793 Free article.

3

Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells.

Maloney DG, Brown S, Czerwinski DK, Liles TM, Hart SM, Miller RA, Levy R. Maloney DG, et al. Among authors: czerwinski dk. Blood. 1992 Sep 15;80(6):1502-10. Blood. 1992. PMID: 1520877 Free article. Clinical Trial.

4

Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon.

Brown SL, Miller RA, Horning SJ, Czerwinski D, Hart SM, McElderry R, Basham T, Warnke RA, Merigan TC, Levy R. Brown SL, et al. Blood. 1989 Feb 15;73(3):651-61. Blood. 1989. PMID: 2465039 Free article.

5

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R. Maloney DG, et al. Among authors: czerwinski dk. Blood. 1994 Oct 15;84(8):2457-66. Blood. 1994. PMID: 7522629 Free article. Clinical Trial.

6

Clinical trials of idiotype-specific vaccine in B-cell lymphomas.

Hsu FJ, Kwak L, Campbell M, Liles T, Czerwinski D, Hart S, Syrengelas A, Miller R, Levy R. Hsu FJ, et al. Ann N Y Acad Sci. 1993 Aug 12;690:385-7. doi: 10.1111/j.1749-6632.1993.tb44039.x. Ann N Y Acad Sci. 1993. PMID: 8368764 Clinical Trial. No abstract available.

7

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells.

Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Hsu FJ, et al. Nat Med. 1996 Jan;2(1):52-8. doi: 10.1038/nm0196-52. Nat Med. 1996. PMID: 8564842

8

Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial.

Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R. Hsu FJ, et al. Blood. 1997 May 1;89(9):3129-35. Blood. 1997. PMID: 9129015 Free article. Clinical Trial.

9

Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone.

Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R. Davis TA, et al. Among authors: czerwinski dk. Blood. 1998 Aug 15;92(4):1184-90. Blood. 1998. PMID: 9694706 Free article. Clinical Trial.

10

Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.

Davis TA, Czerwinski DK, Levy R. Davis TA, et al. Among authors: czerwinski dk. Clin Cancer Res. 1999 Mar;5(3):611-5. Clin Cancer Res. 1999. PMID: 10100713

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

70 results

Search Page